United Therapeutics (UTHR) Depreciation & Amortization (CF) (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $22.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 14.14% year-over-year to $22.6 million; the trailing twelve-month figure through Mar 2026 stood at $88.4 million (up 14.36% YoY), and the FY2025 full-year result was $85.6 million, up 18.07% from the prior year.
• Depreciation & Amortization (CF) declined to $22.6 million in Q1 2026, from $22.8 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $22.8 million in Q4 2025 to a low of $12.5 million in Q1 2022.
• A 5-year average of $16.8 million and a median of $15.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) changed 0.0% in 2022 and jumped 44.96% in 2024, its largest moves.
• Tracing UTHR's Depreciation & Amortization (CF) over 5 years: stood at $13.2 million in 2022, then rose by 3.79% to $13.7 million in 2023, then jumped by 43.8% to $19.7 million in 2024, then increased by 15.74% to $22.8 million in 2025, then decreased by 0.88% to $22.6 million in 2026.
• Business Quant data shows UTHR's Depreciation & Amortization (CF) at $22.6 million in Q1 2026, $22.8 million in Q4 2025, and $21.9 million in Q3 2025.